Small, smart and powerful – Anton Paar's MCP 150 polarimeter impresses with its sophisticated features
Anton Paar`s compact MCP 150 polarimeter is a one-size-fits-all solution: Although it is compact, it provides full 21 CFR Part 11 compliance, including electronic signature requirements. The easy-to-use touchscreen supports fast navigation with unmatched simplicity. Multiple measurement capabilities and customized methods make both, routine and unique measurements better than ever. This model is equipped with an enhanced accuracy (± 0.005 °OR), for extremely high precision measurement. The powerful Peltier temperature control guarantees fast and even temperature distribution of the sample within the range of 15 °C to 35 °C. With the intelligent Toolmaster™ technology, information on all relevant parameters is wirelessly transferred to the instrument. This eliminates user errors and ensures that every change is recorded in the Audit Trail. LIMS and FTP connectivity are fully supported.
For more information on MCP 150 and other Anton Paar solutions, visit www.anton-paar.com.
Anton Paar GmbH was established in 1922 as a one-man locksmith’s workshop. Today, over 2,000 employees worldwide develop, produce and distribute high-quality measuring instruments for the determination of properties such as density, temperature and viscosity as well as high-precision mechanical parts and assemblies. Anton Paar has strong links with universities and research laboratories worldwide. The company is owned by the Santner Foundation, which invests in research in the field of science and technology as well as in the rehabilitation of drug addicts.
www.anton-paar.cominfo@anton-paar.com
Market Demands and Emerging Technologies Shape Outsourcing Models
June 5th 2025Trends in certain forms of drug delivery, as well as the emergence of artificial intelligence, are playing roles in evolving the nature of partnerships, but there are new types of partnerships gaining steam as well.
Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries
May 30th 2025In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) vectors, as viewed by two industry experts who recently exhibited at the annual ASGCT meeting.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
The Role of On-Demand Manufacturing and Derisking in Accelerating Early Clinical Trial Success
June 4th 2025Small pharmaceutical companies are constantly seeking innovative solutions to streamline early clinical trials. Adaptive clinical trials offer important benefits to sponsors and patients, both from a commercial and ethical standpoint. These trials offer flexibility and efficiency, especially in the early stages, where trial protocols can be adjusted based on interim data, such as introducing new doses or modifying participant sample size. However, adjusting manufacturing demand during an adaptive trial can be complicated, and strict regulatory requirements present significant challenges. On-demand manufacturing provides a robust solution, allowing for real-time supply and demand adjustments and improved trial flexibility. This paper explores how on-demand manufacturing meets the operational needs of adaptive trials and aligns with regulatory expectations.
